UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...

A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

“This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." The post ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...